| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8787530 | Journal of Thoracic Oncology | 2018 | 7 Pages |
Abstract
TAPOs are frequently observed with osimertinib treatment and may be mistaken for isolated pulmonary progression or drug-induced ILD. Given the lack of serious clinical deterioration, it is reasonable to continue osimertinib with regular computed tomographic-scan follow-up. For further clinical validation of TAPOs, long-term follow-up and large studies are warranted.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Hansang Lee, Ho Yun Lee, Jong-Mu Sun, Se-Hoon Lee, Youjin Kim, Song Ee Park, Jin Seok Ahn, Keunchil Park, Myung-Ju MD, PhD,